logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics looks to unlock further potential after 'transformational' year

Snapshot

  • Strong pipeline of pre-clinical drug candidates 
  • Moving into the clinical trial phase later this year
  • Major collaboration with US biopharma Mallinckrodt
science

Quick facts: Silence Therapeutics PLC

Price: 256 GBX

AIM:SLN
Market: AIM
Market Cap: £200.52 m
Follow

 

What does Silence do?

The name provides a hint. It is a specialist in the field of gene silencing. Its technology uses RNA interference, a biological process in which RNA molecules inhibit gene expression or translation, by neutralising targeted molecules.

 

 

How’s it doing

Silence Therapeutics PLC (LON:SLN) has made a clinical trial application for its lead candidate, SLN124, which is being developed to treat iron overload disorders.

SLN124 already has orphan drug designation in Europe, which could shorten its timeline to market while providing the approved product with additional exclusivity.

Silence describes SLN124 as a “promising candidate medicine” for patients with iron overload disorders such as ß -Thalassemia, Myelodysplastic Syndrome and Hereditary Hemochromatosis.

A phase Ib, first-in-human trial is scheduled to start in the third quarter.

Another drug in Silence’s pipeline is SLN500, which will be used to treat rare diseases.  Silence announced in July that it has agreed a partnership with US biopharmaceutical firm Mallinckrodt PLC (NYSE: MNK) for SLN500.

Silence will be responsible for taking SLN500 through pre-clinical studies and a phase I trial. After that, Mallinckrodt will take over clinical development and responsibility for global commercialisation.

Meanwhile, an investigational new drug/clinical trials application for SLN360, a treatment for a range of cardiovascular disease, is anticipated to be filed in the second half of 2020.

 

Watch the interview

 

What the boss says:

In the group’s 2018 results statement in March, chief executive David Horn Solomon said:  "2018 was a defining year for Silence Therapeutics, with transformational change throughout the business.

“With the first RNAi therapeutics now approved by the FDA, effectively creating a new class of medicines, we are working hard to consolidate our position as a leading developer in this exciting new field.

“During the year we have made great progress in advancing our lead product SLN124 towards the clinic and we are due to commence in-human clinical trials later in 2019 to demonstrate safety and tolerability.

"We look forward to unlocking more of Silence Therapeutics' potential in 2019 and beyond for the benefit our shareholders and, importantly, for the patients of these devastating conditions."

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics hits first milestone in Mallinckrodt deal

Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment. The UK specialist in RNA therapeutics has already...

3 weeks ago

2 min read